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The low therapeutic ndex of established antiepileptic drugs coupled with a better understanding of the 
pathophysiology of seizure production has led to the development of a range of new therapeutic agents for the 
treatment ofepilepsy. In this review, the three drugs recently licensed in the UK (vigabatrin, lamotrigine and 
gabapentin) are profiled, together with several of the more promising up-and-coming cofilpounds (oxcarbaze- 
pine, felbamate, tiagabine, stiripentol, remacemide and topiramate). Future avenues for clinical research in 
the pharmacological management of he epilepsies involve their rational use both singly and in combination. 
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INTRODUCTION 
Epilepsy is a common condition with a point 
prevalence of just under 1% of a given popu- 
lation 1. There are, by implication, around 
500 000 people in the UK alone who have epi- 
leptic seizures, fewer than 70% of whom will 
have them fully controlled with the currently 
available antiepileptic drugs 2. Many patients, 
particularly those with underlying anatomical 
lesions, respond poorly to monotherapy and are 
treated with combinations of anticonvulsants 
that often cause disabling side-effects with 
only an outside chance of significantly im- 
proved seizure control. 
Dose-related side-effects and idiosyncratic 
reactions are all too common with existing 
anticonvulsants. The tendency to produce 
headache, nausea, dizziness, drowsiness, cogni- 
tive impairment and other central nervous 
system side-effects i almost universal 2.Their 
potential for teratogenicity 3'4and for deleteri- 
ous drug interactions 5 make their long-term 
use problematical. The last few years have 
been exciting times for epileptologists. There 
has been a rush of interesting new antiepilep- 
tic drugs into clinical development. 
THE BASIS OF SEIZURES 
Histologically, epileptic neuronal tissue often 
shows only non-specific changes uch as gliosis 
or dendritic degeneration 6'7. The biochemical 
interplay at the site of epileptogenesis is more 
interesting, and an understanding of the 
pathogenesis may lead us to alter successfully 
the subtle biochemical imbalances responsible 
for seizure generation and propagation. Recent 
advances in drug development have focused on 
the therapeutic potential of manipulating 
brain neurotransmitters. 
Endogenous substances such as gamma mi- 
nobutyric acid (GABA), adenosine and glycine 
are thought o be of importance in inhibiting 
seizure spread 7. Stimulation of the GABAA 
receptor esults in an influx of chloride ions, 
stabilizing the neuronal membrane and pre- 
venting seizure activity. Work in primates has 
demonstrated a selective loss of such terminals 
in epileptogenic foci s, implying a local deficit in 
inhibition. There is decreased binding, also, to 
the GABA/benzodiazepine r ceptor complex in 
temporal lobe lesions 9. 
The role of the excitatory amino acids, es- 
pecially glutamate and aspartate, has been 
well recognized for a number of years. Recep- 
tors for these and other dicarboxylic acids are 
present in altered density in patients with 
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Table 1 : Pharmacological profile of a range of new antiepileptic drugs 
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Drug Mode of action Half life Elimination Concentrations Effect on other 
(hours) affected by... AEDs 
Felbamate ? Glycine antagonist 14-22 
at NMDA receptor 
Gabapentin ? Inhibition of L-amino 5-7 
acid transport 
Lamotrigine Blocks Na channels 25-29 
decreasing EAA 
release 
Remacemide Non-competitive 
NMDA antagonist 
3-5 
(metabolite 
12-18) 
Stiripentol ? Inhibition of GABA Variable 
uptake and (saturation 
metabolism kinetics) 
Tiagabine Decreases GABA 4-13 
reuptake 
Topiramate Unknown 18-23 
Vigabatrin Decreases GABA 5-7 
metabolism 
Hepatic metabolism, Enzyme inducers PHT, VPA 1' 
some renal excretion CBZ 
Renal excretion Nil Nil 
Hepatic glucuroni- Enzyme inducers CBZ 
dation and inhibitors (pharmacodynamic 
interaction) 
Hepatic metabolism Enzyme inducers PHT, CBZ, T 
(active metabolite) and inhibitors 
Hepatic metabolism Enzyme inducers PHT, CBZ, PB 
and inhibitors 
Hepatic metabolism ? Nil ? Nil 
Renal excretion, some Unknown Unknown 
hepatic metabolism 
Renal excretion Nil PHT 
NMDA, n-methyl-D-aspartate; EA_A, excitatory amino acid; AED, antiepileptic drugs; GABA, gamma minobutyric a id; 
PHT, phenytoin; VPA, sodium valproate; CBZ, carbamazepine; PB, phenobarbitone. 
either generalized 1° or temporal obe 11 seiz- 
ures. This implicates the excitatory system in 
producing a micro-environment conducive to 
epileptogenesis. These processes and their 
interplay are important factors in determining 
the extent of the neurological instability 
underlying the ictal diathesis 12. 
ESTABLISHED ANTICONVULSANTS 
The last two first-line anticonvulsants o be 
introduced in the UK were carbamazepine in 
1967 and sodium valproate in 1974. These are 
still the best drugs for controlling most types of 
seizures. There remains, however, a great deal 
of scope for improving our treatment of epi- 
lepsy. Fewer than 70% of patients are ad- 
equately controlled with antiepileptic mono- 
therapy 13. The addition of a second or third 
drug will provide substantial improvement in
only around 10% of the remainder 2. The more 
antiepileptic drugs the patient takes, the 
greater the incidence of adverse effects, par- 
ticularly cognitive impairment and teratoge- 
nesis. 
The modes of action of established antiepi- 
leptic drugs are,multiple, complex and overlap- 
ping TM. Their effects on the central nervous 
system are widespread and rather indiscrimi- 
nate - -a  neuropharmacological blunderbuss 
rather than a laser! The introduction of three 
new anticonvulsants with novel mechanisms of
action in the UK over the last 5 years has revo- 
lutionized our approach to refractory epilepsy. 
Vigabatrin, lamotrigine and gabapentin have 
led the way for a plethora of newer agents that 
are being extensi.vely tested in scienifically- 
based studies world-wide. 
This review will deal with the compounds 
that are breaking through in the routine man- 
agement of epilepsy, and will focus also on the 
most promising drugs currently undergoing 
clinical trials. The pharmacological profiles of 
the anticonvulsants featured in this paper are 
summarized in Table 1. Their potential ranges 
of efficacy are outlined in Table 2. 
NEW ANTIEPILEPTIC DRUGS 
Vigabatrin 
Vigabatrin was licensed in the UK for use as 
add-on therapy for refractory epilepsy in 1989. 
It is being increasingly used in Europe, Africa 
and Asia, but still awaits regulatory approval 
in North America. 
Mode of action 
Vigabatrin is a GABA analogue which acts as 
a 'suicide' inhibitor of GABA-transaminase 
(Fig. 1). It binds irrevocably to its target 
enzyme, and so facilitates GABA-ergic inhi- 
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Table 2: Efficacy of a range of new antiepileptic drugs against common seizure types 
Par t ia l  Secondary  genera l i zed  Ton ic -c lon ic  Absence  Myoc lon ic  
Fe lbamate  + + ? ? ? 
Gabapent in  + + ? - - 
Lamotr ig ine  + + + + -I- 
Oxcarbazep ine  + + + - - 
Remacemide  + + ? ? ? 
S t i r ipento l  + + ? + ? 
T iagab ine  + + ? ~ ? 
Top i ramate  + + ? ? ? 
V igabat r in  + + ? - - 
bition by interfering with its catabolism is.
Other possible modes of action have been also 
suggested ~6. 
Pharmacokinetics and interactions 
Vigabatrin is well absorbed after oral adminis- 
tration, with peak concentrations occurring 
around 3 hours after dosing 17. Although it is 
given as a racemic mixture, only the S-enan- 
tiomer has a significant pharmacological 
effect. The drug is excreted unchanged in the 
urine, with an elimination half-life of around 6 
hours 17. Because of the irreversible action on 
its target enzyme, vigabatrin's pharmacologi- 
cal effect lasts longer than is suggested by its 
pharmacokinetics--perhaps as much as 48 
hours 18. Vigabatrin is not significantly protein 
bound, and does not induce or inhibit hepatic 
metabolism. It decreases the phenytoin concen- 
tration by around 20% by an unknown mech- 
anism 19. In only one (open) study has this been 
thought to compromise s izure control 2°. 
Efficacy and tolerability 
Many studies have confirmed the efficacy of 
vigabatrin as add-on therapy, particularly in 
patients with partial seizures with or without 
secondary generalization. On average, 50% of 
patients had their seizure frequency reduced 
by at least half 21. Its effect on generalized 
tonic-clonic seizures is variable, and it can 
exacerbate absences and myoclonic jerks. 
Tolerance is not thought o be a factor in its 
long-term use, with efficacy demonstrated for 
up to 7 years after initial administration 22'23. 
There appears to be a ceiling to effective dosing 
in individual patients 24. For most, this occurs 
around 2-3 g of vigabatrin daily 25. 
A review of over 2000 patients on vigabatrin 
gave the incidence of drowsiness at 10%, with 
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Fig. I : Structure of GABA and vigabatrin. 
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dizziness, headache, diplopia, ataxia and ver- 
tigo reported in approximately 2% 21 . Tolerance 
to vigabatrin's sedative effects can be 
expected 26. Psychiatric problems following its 
introduction, such as anxiety, depression and 
aggression are well recognized. The precipi- 
tation of psychosis at high dosage or following 
its sudden withdrawal contraindicates vigaba- 
trin's use in patients with a history of behav- 
ioural disturbance 21.Accordingly, initial dos- 
ing should be low (0.5-1 g daily) with careful 
titration to a maximum of 2-3 g daily in the 
majority of patients 27. 
Lamotrigine 
Folic acid was shown to have proconvulsant 
properties in the mid-1960s. Accordingly, anti- 
epileptic drug development a  the Wellcome 
Institute concentrated onfolate antagonism as 
a method of identifying potential new antiepi- 
leptic drugs. Lamotrigine was born out of this 
search, although it is now known that these 
properties are not linked. 
Mode of action 
Lamotrigine is chemically and functionally 
unrelated to the other antiepileptic drugs (Fig. 
2). Its anticonvulsant effect arises from a 
blockade of sodium channels, limiting the pre- 
synaptic release of glutamate and aspartate 
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and, thus, stabilizing neuronal membranes 2s.
This, however, is unlikely to be the whole 
story  29 
Pharmacokinetics and interactions 
Oral administration f lamotrigine l ads to its 
rapid and near complete absorption. The elim- 
ination half-life is around 29 hours with 
metabolism largely by hepatic glucuronida- 
tion 3°. Interestingly, patients with Gilbert's 
disease have a longer half-life due to a decrease 
in the activity of the enzyme bilirubin uridine 
diphosphate glucuronyl transferase 31.
Lamotrigine does not itself induce or inhibit 
hepatic enzymes. Consequently, it has no influ- 
ence on the metabolism of other lipid soluble 
drugs, including the oral contraceptive pill and 
warfarin. Sodium valproate has been shown to 
lengthen its half-life to around 59 hours, and 
the enzyme-inducing anticonvulsants, carba- 
mazepine, phenytoin and phenobarbitone 
reduce it to around 12 hours 32. There have 
been reports of symptoms of neurotoxicity 
(headache, nausea, dizziness, diplopia, ataxia) 
in patients taking carbamazepine in whom 
lamotrigine has been introduced 33. These dis- 
appear when the dose of either drug is reduced. 
This is thought o be the clinical represen- 
tation of a pharmacodynamic interaction 34. 
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Fig. 2: Structure of lamotrigine. 
Sedation is not a prominent manifestation of
lamotrigine toxicity 49. 
Double-blind trials to assess the usefulness 
of lamotrigine as monotherapy, using carba- 
mazepine and phenytoin as comparators have 
just been completed. Preliminary results 
suggest equal efficacy to carbamazepine and 
phenytoin with better tolerability. Other com- 
parative studies in children, in the primary 
generalized epilepsies and in the elderly are 
underway. The starting dose and titration rate 
will depend on existing treatment s° when the 
drug is used as adjunctive therapy (Table 3). 
Lamotrigine is usually prescribed twice daily, 
but a single daily dose can be used if the drug is 
combined with sodium valproate or as mono- 
therapy. A low, slow introduction schedule will 
reduce the likelihood of rash. 
Efficacy and tolerability 
Ten double-blind, placebo-controlled, add-on 
studies have been carried out with lamotri- 
gine 35-44, nine of which reported success 
against partial seizures with or without 
secondary generalization. Many open studies 
have confirmed these findings 4s. Clinical ex- 
perience also suggests that lamotrigine is ef- 
fective for the primary generalized epilep- 
sies 46. There is anecdotal evidence too to 
support its value in Lennox-Gastaut syn- 
drome 47. These observations have not yet been 
substantiated in controlled clinical trials. 
Lamotrigine is a well-tolerated drug, with 
skin rash being the most common reason for 
withdrawal. This occurs in approximately 3% 
of patients and depends on the rate of introduc- 
tion of the drug 4s. Side-effects such as dizzi- 
ness, headache, nausea nd vomiting, ataxia, 
diplopia and tremor are other minor problems 
associated with lamotrigine administration. 
Table 3: Lamotrigine dosage and titration schedules 
1. Add-on in treated adults and adolescents 
Weeks 1-2 
Weeks 3-4 
Maintenance 
Valproate Others 
25 mg alt die 50 mg daily 
25 mg daily 50 mg twice 
daily 
50-100 mg twice 100-200 mg twice 
daily daily 
2. Add-on in treated children 
Valproate Others 
Weeks 1-2 0.2 mg/kg 2 mg/kg 
Weeks 3-4 0.5 mg/kg 5 mg/kg 
Maintenance 1-5 mg/kg 5-15 mg/kg 
3. Monotherapy in newly diagnosed epilepsy 
Adults Children 
Weeks 1-2 25 mg daily 0.5 mg/kg 
Weeks 3-4 25 mg twice 1 mg/kg 
daily 
Maintenance 50-100 mg twice 2-8 mg/kg 
daily 
Higher doses can be tried if seizures persist and the 
patient is tolerating the drug without complaint. 
Gabapentin 
H 3N + CO~ 
[ I 
Gabapentin, a chemical analogue of GABA, 
was intended to act as a GABA agonist (Fig. 3). 
It was thought too that, being hydrophilic, 
blood-brain barrier penetration would be fa- 
cilitated. 
Fig. 3: Structure of gabapentin. 
Mode of action 
Oxcarbazepine 
Interestingly, the anticonvulsant properties of 
gabapentin are not dependent on any direct 
action on the GABA-ergic system 51. The drug 
appears to bind to a membrane site near the 
glutamate receptor, which may represent a
transport system for L-amino acids 52'53. A 
recent study suggests that gabapentin may 
also limit the rate of firing of sodium-depen- 
dent action potentials 54. 
gabapentin's efficacy against partial seiz- 
ures 5s. A clear-cut dose-response relationship 
in reducing partial and secondary generalized 
seizures has been demonstrated with the 
drug 59. In a large double-blind, parallel group, 
placebo-controlled study involving 127 
patients with drug-resistant partial seizures, 
25% of these taking gabapentin experienced a 
reduction in seizure frequency exceeding 
50% 6°. The therapeutic effect of gabapentin 
has been shown to persist for up to 24 
months 6~. 
Adverse events with gabapentin are gener- 
ally mild and transient 62. The most common 
are somnolence, fatigue, dizziness and weight 
gain. Other problems include diplopia, head- 
ache, ataxia and nausea. No idiosyncratic reac- 
tions have been reported to date. Early reports 
are reassuring also regarding its lack of terato- 
genic potential 63. 
The recommended schedule for prescribing 
gabapentin involves thrice daily adminis- 
tration. However, some patients appear to re- 
spond to a morning and evening dose. The drug 
should be introduced over the first week at low 
dosage (e.g. 300 mg twice daily) and thereafter 
can be increased more rapidly as necessary toa 
maximum of 2700 mg daily or thereabouts. Its 
use is not currently recommended in children 
under 12 years of age. 
Pharmacokinetics and interactions 
Oral dosing of gabapentin results in rapid 
absorption, and the drug has a bioavailability 
of 60%. A saturable transport mechanism in 
the gut explains the lack of proportionality be- 
tween increased oses and levels in plasma 55. 
Maximum concentrations occur 2-3 hours 
after administration a d the elimination half- 
life approximates 5-7 hours B6. There is no sig- 
nificant protein binding, and the drug is 
excreted unchanged in the urine with clear- 
ance rates equivalent to those for creatinine. 
The lack of important drug interactions with 
gabapentin has been widely reported 57. 
Efficacy and tolerability 
A small, dose-ranging, double-blind cross-over 
study was the first to provide evidence for 
0/ '~ NH 
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Fig. 4: Structure of oxcarbazepine. 
Oxcarbazepine, the 10-keto analogue of carba- 
mazepine (Fig. 4), has been licensed for use in a 
number of countries worldwide. Its metabolism 
differs from that of the parent compound and 
this holds out the possibility of a more benign 
side-effect profile with fewer drug interac- 
tions 64. 
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Mode of action 
The mode of action of oxcarbazepine is similar 
but not identical to that of carbamazepine 65. 
Its major effect, therefore, is in preventing 
burst firing of neurones by blocking voltage- 
dependent sodium channels. 
Pharmacokinetics and interactions 
Oxcarbazepine is a pro-drug, the main active 
principle being 10,11-dihydro-10-hydroxy-car- 
bamazepine which is largely eliminated by 
hepatic glucuronidation 63. This moiety is 55% 
bound to.plasma proteins and has an elimin- 
ation half-life approximating 9 hours. Unlike 
carbamazepine, oxcarbazepine does not 
undergo autoinduction of metabolism 66. The 
drug has no effect on the metabolism of other 
anticonvulsants 67. However, the area under 
the concentration-time curve of the active 
metabolite is lower in patients taking carba- 
mazepine, phenytoin and phenobarbitone than 
in controls uggesting a small, probably clini- 
cally irrelevant, induction effect of these drugs 
on its elimination 67'6s. 
Oxcarbazepine has less potential than carba- 
mazepine to induce liver enzymes and so influ- 
ence the metabolism ofother drugs. It appears 
to induce selectively a single isoform of cyto- 
chrome P450, namely IIIA 69. Volunteer studies 
have suggested that it does not interfere with 
warfarin metabolism 7°,nor will cimetidine 71
or dextropoxyphene 72 inhibit its breakdown. 
However, decreased bioavailability of the oral 
contraceptive pill has been noted in some 
patients treated with oxcarbazepine 73. 
Efficacy and tolerability 
Several double-blind, add-on studies have con- 
firmed comparable efficacy between oxcarbaze- 
pine and carbamazepine 74-76. In addition, no 
difference in anticonvulsant effect was found 
between oxcarbazepine and carbamazepine in 
patients with newly diagnosed epilepsy 77. Like 
carbamazepine, oxcarbazepine has no place in 
the treatment of absence seizures and myo- 
clonic jerks 69. 
Comparisons with carbamazepine have sug- 
gested a lower incidence of minor side- 
effects 7~-77. Those most commonly associated 
with oxcarbazepine are diplopia, nausea, head- 
ache, dizziness, drowsiness and ataxia 69. 
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Oxcarbazepine, like carbamazepine, has a pro- 
pensity to cause hyponatraemia in some 
patients 7s. However, it produces fewer rashes 
than carbamazepine 79 and perhaps other idio- 
syncratic reactions 69. 
Felbamate 
Felbamate is a dicarbamate d rivative (Fig. 5) 
which is licensed in the United States and has 
recently gained approval for use in partial seiz- 
ures and Lennox-Gastaut syndrome in some 
European countries. It has been reported in 
animal models as having an unique profile of 
anticonvulsant activity, with little tendency to 
cause neurotoxicity s°.
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Fig. 5: Structure offelbamate. 
Mode of action 
Felbamate has an interesting effect in de- 
creasing the binding of ligands at the glycine 
site of the n-methyl-d-aspartate (NMDA) 
receptor sl. This implies that it may act as a 
glycine antagonist, possibly diminishing the 
deleterious influence on neuronal function of 
excitatory amino acids. Several other modes of 
action have also been suggested s2.
Pharmacokinetics and interactions 
Oral administration f felbamate l ads to com- 
plete and rapid absorption. Following a single 
dose, the half-life ranges between 14 and 22 
hours in epileptic patients s2. A proportion of 
absorbed rug is excreted unchanged in the 
urine, with the rest undergoing hydroxylation 
and conjugation i the liver. 
On addition of felbamate, phenytoin, val- 
proate and phenobarbitone levels will rise by 
around 20-30%, whereas erum carbamaze- 
pine will fall by a similar amount s3. However, 
this latter effect is offset by greater production 
of the active metabolite, carbamazepine 10,11 
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epoxide s4. Enzyme-inducing antiepileptic 
drugs will increase the rate of clearance of fel- 
bamate sS. The effect of valproate on felbamate 
levels is less clear-cut s6. 
Efficacy and tolerability 
The efficacy of felbamate has been established 
in six major clinical trials involving around 
370 patients 8~-92. Five of these were under- 
taken in patients with partial seizures with or 
without secondary generalization. The final 
piece of evidence consists of a major placebo- 
controlled trial in 73 children with Lennox- 
Gastaut syndrome, each of whom had at least 
90 atonic or atypical absence seizures per 
month despite treatment with one or two 
established antiepileptic drugs. Felbamate 
reduced the frequency of atonic seizures as well 
as atypical absences 9°. Preliminary results in 
the primary generalized epilepsies are also 
promising. Long-term efficacy data with the 
drug, however, are still limited, although early 
observations are encouraging 93. 
The most frequent side effects with felba- 
mate originate from the central nervous 
system and include diplopia, dizziness, head- 
ache, nausea and vomiting, diarrhoea and 
ataxia s2. Weight loss of around 5% body weight 
has been reported in some patients, probably 
secondary to anorexia nd nausea. Both insom- 
nia and somnolence have been associated with 
felbamate administration s3.
Tiagabine 
Tiagabine, a nipecotic acid derivative (Fig. 6), 
has a powerful anticonvulsant effect in animal 
seizure models 94. 
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Fig. 6: Structure of tiagabine. 
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Mode of action 
Tiagabine acts by inhibiting GABA re-uptake 
by glial cells and presynaptic neurones 95. The 
resultant increase in synaptic GABA concen- 
trations is thought to be responsible for its 
anticonvulsant action 96. 
Pharmacokinetics and interactions 
Tiagabine is well-absorbed orally with peak 
levels occurring around an hour after dosing 94. 
The elimination half-life varies between 4 and 
13 hours. Elimination is mainly by hepatic 
metabolism, which appears not to be 
influenced by concomitant anticonvulsant 
treatment. 
Efficacy and tolerability 
Double-blind studies uggest useful efficacy for 
tiagabine against partial and secondary gener- 
alised seizures 97'9s. Monotherapy trials are 
also currently being undertaken 99. Side-effects 
so far have been largely confined to headache, 
dizziness and sedation. 
Remacemide 
Remacemide was designed to affect the excit- 
atory component of epileptogenesis. It has 
recently entered phase III clinical trials in epi- 
leptic patients. 
Mode of action 
Remacemide is chemically unrelated to any 
other anticonvulsant (Fig. 7) and has been 
shown to be a weak, non-competitive NMDA 
antagonist 1°°. At least part of remacemide's 
anticonvulsant action is thought o be due to 
its main metabolite, the desglycinate. 
Pharmacokinetics and interactions 
Oral dosing of healthy volunteers shows 
absorption to be rapid, peak levels being 
attained around 1 hour after administration. 
The parent drug has an elimination half-life 
approximating 4 hours, whereas the active 
desglycinate metabolite has a longer half-life 
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Fig. 7: Structure of remacemide. 
in the region of 12-18 hours l°°. This difference 
in pharmacokinetics between parent drug and 
active metabolite is important in determining 
the optimum frequency of dosing. 
Though not yet complete, interactions 
studies with remacemide suggest hat it may 
act as an enzyme inhibitor, slowing the metab- 
olism of both phenytoin and carbamazepine ~°1. 
Clearance of remacemide is increased in 
patients taking phenytoin and carbamazepine 
compared with those treated with sodium val- 
proate 1°2. 
Efficacy and to/erabi/ity 
Preliminary results with remacemide suggest 
useful efficacy against partial and secondary 
generalized seizures 1°3'1°4. In common with 
other centrally acting drugs, lightheadedness, 
diplopia and dizziness have been reported as 
well as gastro-intestinal symptoms uch as 
dyspepsia, nausea and vomiting. Aggressive 
behaviour has been noted on rare occasions. No 
evidence of idiosyncratic reaction to the drug 
has so far emerged. 
Stiripentol 
Mode of action 
No precise mechanism ofaction has been deter- 
mined, but laboratory studies suggest that 
stiripentol increases GABA levels either by in- 
hibiting synaptosomal uptake or by decreasing 
its metabolism l°s 
Pharmacokinetics and interactions 
The drug is slowly distributed rendering its 
elimination curve multiphasic. It is highly pro- 
tein bound and undergoes non-linear kin- 
etics 1°9. Stiripentol is biotransformed mainly 
by hepatic metabolism H°, and this can be ac- 
celerated by other antiepileptic drugs 111. It 
strongly inhibits the metabolism of other anti- 
convulsants, causing a rise in concomitant phe- 
nytoin, carbamazepine, sodium valproate and 
phenobarbitone112,113 
Efficacy and to/erabi/ity 
Most of the studies carried out so far have been 
open label design in patients with partial seiz- 
ures with or without secondary generaliz- 
ation111,114. A preliminary report supports effi- 
cacy in children with atypical absences 115. 
Overall, stiripentol is well tolerated with only 
ataxia, nausea, vomiting and lethargy cur- 
rently complicating its clinical use. 
Topiramate 
Topiramate (Fig. 9) is yet another antiepileptic 
compound, which is structurally distinct from 
all other comparable drugs! 
Stiripentol (Fig. 8) has been shown to be an O 
effective anticonvulsant in many animal seiz- 7 ~ ,O  
ure models 1°5-1°~. SO=NH2 
Y . .  OH 
"~ ~c- -c  I c"  ~c / C CH 3 - / 
J. II i o.. -o -  I 
'~ , "~ '~ o CH 3 CH 3 
Fig. 8: Structure of stiripentol. Fig. 9: Structure of topiramate. 
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Mode of action 
As with many of the new anticonvulsants, this 
is presently uncertain. One study suggests that 
it may enhance GABA-mediated chloride ion 
influx ll6. 
Pharmacokinetics and interactions 
Topiramate is slowly absorbed after oral dos- 
ing, peak concentrations in plasma occurring 
between 1 and 4 hours after administration. 
The drug is excreted largely unchanged in the 
urine, with an elimination half-life ranging 
from 19 to 23 hours 11~. Around 5~ of a dose 
undergoes hepatic metabolism. Interactions 
with other anticonvulsants have still to be 
fully delineated. 
Efficacy and tolerability 
A number of double-blind, placebo-controlled 
studies have been completed with topiramate 
in adults with refractory partial seizures with 
or without secondary generalization ~ls'~m 
These have shown a good response (defined as a 
reduction of >50c~ in seizure frequency) in 
more than half of the patients taking more 
than 200 mg of the drug per day ~2°" v~l. Prelimi- 
nary data also suggest efficacy in the Lennox- 
Gastaut syndrome ~2'~. Topiramate appears 
likely to be a valuable add-on treatment in 
refractory epilepsy ~23. 
The most frequently reported side-effects 
with topiramate include ataxia, cognitive dys- 
function, dizziness, headache, nausea, nystag- 
mus, tremor and visual disturbance. Less 
common problems include mood lability and 
weight loss. Animal toxicity studies suggest 
that topiramate may be teratogenic. 
CONCLUSIONS 
The recent developments in the pharmacother- 
apy of epilepsy are providing formidable chal- 
lenges to the clinician. Which patients should 
receive which drug and for which seizure type? 
So far, most is known about lamotrigine and 
vigabatrin, as these have been in general use 
for some years. Felbamate and gabapentin 
have been licensed more recently in the USA 
and approved for licensing in some European 
countries. Oxcarbazepine, also generally avail- 
13 
able in some countries, appears to be better 
tolerated than carbamazepine. These drugs are 
undoubtedly valuable in the treatment of 
refractory epilepsy. The early clinical promise 
of tiagabine and remacemide are indicators 
that these compounds too will make the tran- 
sition from interesting chemicals to useful 
therapeutic agents. Stiripentol and topiramate 
show a few more problems, but may well prove 
valuable as second-line therapy in refractory 
epilepsy. The drugs touched on in this review 
are merely the tip of a growing iceberg. 
For an antiepileptic drug to demonstrate 
efficacy in refractory epilepsy is impressive. 
Their use as adjunctive therapy, however, is 
likely to exaggerate their side-effect profiles. 
The level playing field of double-blind, con- 
trolled trials in previously untreated patients 
will demonstrate the true worth of these new 
drugs in comparison with the much less expen- 
sive and more established compounds. Mono- 
therapy may well prove the newer crop of anti- 
convulsants more benign. So far, only 
felbamate has been licensed for this indication, 
although lamotrigine is likely to be available 
soon as monotherapy in Europe. 
The ultimate goal for everyone involved in 
the development of antiepileptic drugs is the 
discovery of effective and safe agents with 
well-defined mechanisms of action. We may 
find it a useful strategy to combine drugs that 
independently influence either excitatory or 
inhibitory processes. As time passes, the best 
combinations are likely to be discovered seren- 
dipitously. The use of two agents acting on the 
'same side of the fence', such as vigabatrin and 
tiagabine, may be a logical approach in refrac- 
tory single seizure types. Those with different 
modes of action, such as vigabatrin and lamo- 
trigine, may be best combined for patients ex- 
periencing more than one seizure type. A nar- 
rower range of biochemical effects may lead to 
enhanced tolerability during such dual ther- 
apy, and 'selective' co-prescribing could be the 
key to improving seizure control with fewer 
side effects. This approach should supersede 
the current empiricism, and lead to the 
rational evolution of combination therapy for 
the treatment of refractory epilepsy. 
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